A Agilent Technologies Inc.

Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award

(NYSE: A) today announced that the raw material identity verification system has received a 2020 R&D 100 Award in the Analytical/Test category. The worldwide competition, held by , recognizes R&D pioneers and their revolutionary contributions to science and technology.

Agilent’s award-winning product is the first handheld Raman spectrometer incorporating spatially offset Raman spectroscopy (SORS) technology for the quick identification of raw material through containers. It is specifically designed for use in cGMP-governed raw material identification processes.

The award win is a testimony to the quality of innovation that went into developing the handheld system. “The product launched in March of this year, and users are already seeing productivity gains,” said Philip Binns, vice president and general manager of Agilent's Spectroscopy Division. “With raw material testing for improved product quality on the rise in the pharmaceutical and biopharmaceutical industries, customers need to minimize risk to be compliant with increasingly stringent regulations. This product will help them do that.”

The addition of Vaya to the spectroscopy product portfolio now provides an Agilent solution that addresses the entire raw material ID market with a highly differentiated offering. One important distinction of the Vaya is its ability to identify raw materials through transparent and non-transparent containers, removing the need for sampling, sampling booths, and QC lab testing. Vaya improves current testing protocols—from low volume sampling to 100% ID testing. Flexible and future-proof, if regulators require more testing, Vaya allows manufacturers to develop higher-throughput testing without any additional equipment. This translates into having the confidence to conduct a faster raw material identification process that is cost-effective and efficient.

Agilent’s Spectroscopy Division has a long history of products that have previously received the R&D 100 Award including, in 2015 the 5100 ICP-OES, 2014 the Cary UMA, 2013 the 8800 ICP-QQQ, 2012 the 4100 MP-AES, and in 1998 the Cary 50.

Established in 1963, the R&D 100 Awards are the only science and technology awards competition that recognizes new commercial products, technologies, and materials for their technological significance available for sale or license. There are six categories in the R&D 100 and four special recognition categories. Often called the ‘Oscars of Innovation’, these winning products and technologies are the 100 disruptors that will change industries and make the world a better place in the coming years.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. In its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
15/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch